This study shows that spontaneous RPE differentiation eliminates most aneuploid human pluripotent stem cells but permits expansion of cells with chromosome 1q gains when they are co-cultured with wild-type cells
0:00Welcome to Base by Base, the papercast that brings Genomix to you wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast app. Imagine a treatment that could cure blindness from age-related macular degeneration.
0:12It's one of the most common causes of vision loss. And this isn't, you know, science fiction anymore. Not at all. It's the promise of human pluropotent stem cells dash HPSEs. The idea is you can turn them into the eye cells you need, these retinal pigment epithelium or RPE cells, and then transplant them.
0:31It sounds revolutionary. And it is. I see there are over a 100 clinical trials already happening. It's a huge area of regenerative medicine. But there's this massive safety cloud that's always been hanging over it.
0:42HPSCs are just inherently unstable. They're, well, they're notorious for picking up genomic abnormalities. Right. Things like gaining or losing whole chromosomes, anaploidy. Exactly. And these changes can look distressingly similar to the very 1st steps of cancer development.
0:57The industry has sort of relied on this assumption that the process of differentiation, you know, forcing the stem cell to become an RPE cell acts as a natural filter. A purifying bottleneck. That's the term.
1:10The thinking is simple. The abnormal cells are unstable, and the stress of becoming a specialized cell should just, well, kill them off. Leaving you with only the healthy cells for the final therapy. But what if one really common mutation has figured out a way to not only survive that filter, but to actually use the healthy cells around it to get through.
1:29So, an error that starts out incredibly rare somehow takes over and ends up dominating the whole population. Precisely. So for our deep dives today, we're going to unpack exactly how a specific chromosomal gain, this game of chromosome, arm one cue, bypasses that critical quality control step. It's a story of some very unexpected, and frankly, risky, cellular teamwork.
1:52Before we get into all the mechanics, we should definitely give a shout out to the research team. Yes, absolutely. We're celebrating the work of Eduard Couvrero de Deckersberg, Yin Yan Lei and their colleagues.
2:01The lab was led by Claudia Spitz at the reuniversitied Brussel. Their work has really advanced our understanding of this whole instability problem. They've shined a much needed spotlight on a major vulnerability in the field.
2:15That's for sure. Okay, so let's set the stage. This genomic instability in stem cells. It's not a rare thing, right? No, it's pervasive. It happens all the time. When you culture these cells for long periods.
2:26They just start acquiring these abnormalities. Most common ones are gains in chromosomes, one, 12, 17, and 20. And the really tricky part is that it exists as low grade mosaicism. So you could have a culture that looks perfectly healthy on a standard genetic screen, but if you look closer, maybe 3 to 6% of the cells are actually carrying one of these errors.
2:46And that's the problem. Standard methods, things like G banding, they're just not sensitive enough. They're designed to find big problems in big populations, not these tiny hidden ones. So if you use a batch of cells with, say, 5% abnormal cells, what's the risk?
3:02Well, at best the therapy just doesn't work as well. But the worst case scenario is that you've transplanted cells that have a 1st hit towards becoming cancerous years down the line. A ticking time bomb, basically, in a patient's eye.
3:15It's a huge liability. Now, we already knew some of these anaployees give the cells an advantage before differentiation. Gain of chromosome 12, for instance, just makes them go faster. Simple proliferation.
3:26And a gain on chromosome 20, specifically the 20 Q11.21 region, makes cells less sensitive to uh, program cell death, epoptosis. So they're tougher. survivors. But can they survive becoming an RPE cell?
3:41That's the key question. And we know some can't. There's another error. Isochromosone 20 Q, and those cells almost always get eliminated during differentiation. They just fail. So the study's central idea was that while some of these errors are a dead end, maybe others actually get a competitive boost during the differentiation process itself.
3:59Exactly, and that they might even become enriched in the final product, using RPE differentiation as the model, was perfect because the clinical stakes are so high. Okay, let's get into the methodology.
4:09This sounds like it required some serious detective work to track these tiny populations. It did. They started with a fairly standard, unguided RPE differentiation protocol. It's a long one, 4 to 8 weeks.
4:23And then they have to purify the cells. Right. They manually pick out the pigmented RPE colonies. The whole process is their experimental bottleneck. And they confirmed it was a very stringent one leading to mostly clonal colonies.
4:37Meaning one cell survives and expands to create a whole cluster. The very definition of selection. So to get that before picture, to see the low grade mosaicism, they needed something with really high resolution.
4:49Which brought them to single cell DNA sequencing. SCDNA sec. They analyzed over 1600 individual cells at the very beginning, and they saw exactly what they expected. The trizomi 12s, the ISO 20 Qs, all the usual suspects.
5:03So they confirmed the problem was there from the start. Pervasive, yes. But here's where it gets interesting. To get the after picture of the final RPE cells. couldn't just use the same method again. Oh, why switch methods?
5:15What was the limitation that forced them to look at RNA to solve the DNA problem? That's a great question. Once RPE sales are fully differentiated, they often stop dividing and getting high quality genomic DNA out of them is really challenging.
5:29So they pivoted. They use single cell RNA sequencing and a clever computational tool called in for CNV. Ah, I see. So in for CNV can infer large DNA copy number changes just by looking at the gene expression levels.
5:43If a whole chromosome arm is duplicated. You see a corresponding jump in the RNA expression from all the genes on that arm. It's an elegant workaround. And I let them analyze a huge number of cells at the end, over 87,000.
5:55But the really clever part was the co-culture experiment. That was the heart of it. They took their anaploid lines, the one Q gain, but also the known failures, like ISO 20 Q, and they differentiated them either alone or mixed in with healthy, wild type cells.
6:08And they tracked them by making the one cue gain cells fluorescent. Right. They started them at this incredibly low frequency, less than half a percent. And then they just watched what happened over the weeks with live imaging.
6:18And this is where the results really start to hit home. They do. First, they confirm the basics. The differentiation bottleneck is ruthless. Almost all the other anapolities they tested, gain of 20 Q, ISO 20 Q, gain of 17 Q.
6:32They were either eliminated, or they just failed to become proper RPE cells. But not the one Q gain. Not at all. It was the complete opposite. The in for CNV analysis of the final purified RPE product showed that the only major genetic imbalance left was the gain of chromosome arm one Q.
6:51And the numbers? Shocking. In one cell line, the one cue gain sales made up nearly 43% of the final population. 43%, from a starting point that was barely detectable. What does that mean for how these therapies are being made right now?
7:04It means that if you're not using these ultrasensitive screening methods before you start, you could be making a product that is overwhelmingly abnormal, even if it looks okay under a microscope. And the key was that they needed the healthy cells to do it.
7:16That's the kicker. They only pulled this off when they were co-cultured. When they were grown alone, they fail. So the abnormal cells are they're parasitic. depending on the healthy cells to do the hard work for them.
7:27That's exactly it. It's a perfect example of cellular rescue. The live imaging confirmed it. Those fluorescent one cue gain cells just exploded, expanding 45 to 124 fold. They were completely out competing their healthy neighbors.
7:42They get rescued, and then they take over. They get rescued, and then they thrive. So let's break down that rescue mechanism. What were the healthy cells giving them in those 1st few critical days? Well, they looked at the cell to cell signaling.
7:55The anaploid cells that failed, like the ones with tries only 20 were just transcriptionally stubborn. They kept expressing plural potency signals like FGF2. They were basically deaf to the instructions to differentiate.
8:06They refuse to grow up. Exactly. But the one Q gain cells were different. Their receptors were ready and waiting for these subtle neuroectodermal signals coming from the wild type cells around them. Like little chemical cues.
8:19Precisely. They identified interactions like NRXN one and LGN one. Those signals were just enough to push the one cue gain cells onto the right path toward becoming RPE. The healthy cells were giving them the map.
8:33So they get the map from their neighbors, but then they unleash some kind of built-in superiority. What's their secret weapon for survival? They have a biological cheat code? It's strongly linked to a single gene called MDM4, which is located right in that gained region on chromosome one key.
8:48MDM 4. That's a key regulator of the P 53 tumor suppressor. Got it. So having an extra copy of one Q means you have more MDM 4 protein, an MDM 4 is a powerful inhibitor in P53. And P53 is the cells emergency brake.
9:02It triggers cell death in response to stress or DNA damage. Right. And differentiation is a very stressful process. So while the normal healthy cells are dealing with that stress and maybe triggering P 53 to self-destruct.
9:13The one Q gain cells have muted that alarm system, they just sail right through. They seal right through and take over the whole culture. But they're not entirely unscathed. When they looked at the gene expression of these one QRPE cells, they saw clear signs of strategy.
9:25So even though they look right. Internally, they're what, fighting to hold it together? Yes. They had upregulated pathways for things like DNA repair and unfolded protein response. They're surviving, but they are under constant internal pressure.
9:39All enabled by that MDM 4 bypass. So the big takeaway here is that this low grade mosaicism isn't harmless at all. It can be actively selected for, creating a final product that's dominated by anaploid cells.
9:52It's a massive vulnerability. And it's important to note, this seems pretty specific to one Q gain for creating functional RPE. Other anaploides that expanded, like the 20 Q gain, mostly just created junk cells that would be filtered out anyway.
10:05The one Q gain is the one that pulls off the complete escape act. It is. Now, we do have to mention the limitations. They use a spontaneous differentiation protocol. Most clinical grade manufacturing today uses more directed protocols with specific growth factors.
10:18Which might change the outcome. It might, it needs more research. And of course, the other huge question is long-term safety. They didn't test whether these one cue gain RPE cells could form tumors after being transplanted in an animal.
10:30So the risk is still theoretical, but the mechanism is like, well, it's undeniably oncogenic. To boil it all down. RPE differentiation is this ruthless filter, but cells with the one q gain are uniquely prepared to beat it.
10:43They get rescued by signals from their healthy neighbors, which gets them on the right path, then they unleash their survival advantage, this MDM 4P 4P 53 bypass, and just dominate the entire culture. Which leaves us with a really provocative thought.
10:56We know these one QRPE cells look the part, they are transcriptionally similar to healthy RPE cells, but we also know they are riddled with internal stress and have a broken P53 pathway, a pathway that's meant to protect us from cancer.
11:10So considering these cells are supposed to last for decades in a person's eye, what does that inherent stress mean for their long-term function? And more importantly, their long-term safety. That's a question the field needs to answer and fast.
11:23This episode was based on an open access article under the CCBY 4.0 license. You can find a direct link to the paper and the license in our episode description. If you enjoyed this, follow or subscribe in your podcast app and leave a 5 star rating.
11:36If you'd like to support our work, use the donation link in the description. Now stay with us for an original track created especially for this episode and inspired by the article you've just heard about.
11:45Thanks for listening and join us next time as we explore more science base by base.
